Brazil, USA) and any size in between (Table 1; Figure 1 ). Working with colleagues around world on these articles has been enjoyable and one of the most rewarding aspects of being the editors for MGGM.
Last, but not least, are the unsolicited, peer-reviewed articles. Many submissions come directly to MGGM, while others are referred from our many high-profile supporter journals published by Wiley, such as Human Mutation, Clinical Genetics, and American Journal of Medical Genetics (AJMG). As submissions have grown since 2013, the number of accepted articles has also steadily increased. Dedicated peer review and editorial evaluation ensures that all published articles meet rigorous scientific standards. As was our hope when the journal started, the topics of the unsolicited, peer-reviewed articles are broad, ranging from diagnosis to treatment as is well illustrated by the titles of the 10 most highly cited manuscripts (Table 2) .
All MGGM articles are deposited in PubMed Central â (PMC) and are indexed and discoverable in PubMed/MED-LINE. MGGM is now in Web of Science (WoS) via indexing in Clarivate Analytics' Science Citation Index Expanded (SCIE). In January 2017, the Founding Editor-in-Chief of MGGM became the third Editor-in-Chief of the American Journal of Medical Genetics Part A (AJMG) (Muenke, 2017) . Moving forward, Max Muenke stepped down as EIC and Suzanne Hart is the Editor-in-Chief of MGGM starting with the January 2018 issue.
What has happened in the field of molecular genetics and genomic medicine over the past 5 years? Highlighted below is just a small selection of topics covered by review articles in the areas critical to our field: (1) technological advances leading to progress in (2) pharmacogenomics, (3) precision medicine in general, and (4) cancer genomics specifically.
Technological advances enabling better and cheaper next generation DNA sequencing (Goodwin, Mcpherson, & Mccombie, 2016; Shendure et al., 2017) , including single cell genome sequencing (Gawad, Koh, & Quake, 2016) , have made the less-than-$1,000 price tag per genome a reality. Despite the availability of tens of thousands of reference genomes such as ExAC (http://exac.broadinstitute. org), ClinVar (http://www.ncbi.nlm.nih.gov/clinvar), and others (Tarailo-Graovac et al. 2017) , high throughput functional validation of variants of unknown significance will continue to be critical in order to determine mechanisms of disease (zebrafish: Hong et al., 2016; mouse: Li et al., 2015; Liu et al., 2017; fruit fly: Zhu, Fu, Nettleton, Richman, & Han, 2017) . Lastly, advances in genome engineering such as the CRISPER/Cas9 systems and others have led to breakthroughs in applications to gene therapy and regenerative medicine (Katrekar, Hu, & Mali, 2017) .
F I G U R E 1 Diagram of countries and geographical localization on the world map for which a manuscript has been published or is in press
Guidelines for the use of pharmacogenomics in clinical practice are available through the Clinical Pharmacogenetics Implementation Consortium (CPIC) (Johnson & Weitzel, 2016; Verbelen, Weale, & Lewis, 2017) . To date, inherited variations in at least 20 genes have been shown to affect more than 80 medications and are actionable in the clinic (Relling & Evans, 2015) . Noninvasive prenatal testing (NIPT) allows for prenatal pharmacogenomics, a "promising area of research" in the near future (Dorfman, Cheng, Hebert, Thummel, & Burke, 2016) .
"The essential job of precision medicine is to match the right drugs to the right patients" (Letai, 2017) . Precision medicine and cancer genomics specifically, have had numerous successes "from preconception to adult medicine" (Ashley, 2016; Rehm, 2017) from personalized treatment of cystic fibrosis to chronic myeloid leukemia and many others. Including diverse populations in human genomics research has become a priority for funding agencies like the National Institutes of Health in the US or the Wellcome Trust in the UK (Hindorff et al., 2018) . Geographical differences in disease susceptibility have been recognized (Sud, Kinnersley, & Houlston, 2017; Tan, Mok, & Rebbeck, 2016) . For example, prostate cancer has a higher incidence and more aggressive course in men of African descent compared to those from Northern Europe. Similarly, differences in incidence of lung cancer, colorectal cancer, and breast cancer have been identified in patients from different countries. Looking forward, we expect that with a decrease in price for medical genome sequencing and easier identification of disease-causing alleles, personalized pharmacogenomics and precision medicine will become a reality for many individuals over the next decade. Looking back has been inspiring, but looking forward is exciting! If the past five years are any indication of the rapid pace of future research, then the next five years in the allied fields of molecular genetics and genomic medicine will be full of new discoveries that will facilitate an improved understanding of the genetic etiology of disease. Such discoveries could in turn provide tools for better patient understanding and disease prevention, or stimulate investment in applied research that might speed the delivery of targeted treatments to the patient bedside. It is within this exciting research environment that the journal Molecular Genetics & Genomic Medicine proudly finds its home. Our journal's Open Access publication policy fully supports the public sharing of scientific knowledge aimed at advancing these admirable goals. As the editors of MGGM, we are honored to be able to publish, and make publicly available, papers representing the widest possible range of human and medical genetics research, and to provide valuable commentaries and global insights on new research and treatment trends. We sincerely thank the Editorial Board, our esteemed peer reviewers, and most of all, the authors and readers of MGGM for this honor.
So, at the start of 2018, we are proud of the accomplishments of MGGM over the past five years and are looking forward to continuing to publish high quality articles in the field in both the American Journal of Medical Genetics and Molecular Genetics & Genomic Medicine. We wish our readers the very best in 2018.
Max 
